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Background. Prospective follow-up studies of large cohorts of patients with glioblastoma (GBM) are needed to assess the effectiveness
of conventional treatments in clinical practice. We report GBM survival data from the Brain Cancer Register of the Fondazione Istituto
Neurologico Carlo Besta (INCB) in Milan, Italy, which collected longitudinal data for all consecutive patients with GBM from 1997 to
2010.
Methods. Survival data were obtained from 764 patients (aged.16 years) with histologically confirmed primary GBM who were diag-
nosed and treated over a 7-year period (2004–2010) with follow-up to April 2012 (cohort II). Equivalent data from 490 GBM patients
diagnosed and treated over the preceding 7 years (1997–2003) with follow-up to April 2005 (cohort I) were available for comparison.
Progression-free survival (PFS) was available from 361 and 219 patients actively followed up at INCB in cohorts II and I, respectively.
Results. Survival probabilities were 54% at 1 year, 21% at 2 years, and 11% at 3 years, respectively, in cohort II compared with 47%,
11%, and 5%, respectively, in cohort I. PFS was 22% and 12% at 1 year in cohorts II and I. Better survival and PFS in cohort II was
significantly associated with introduction of the Stupp protocol into clinical practice, with adjusted hazard ratios (HRs) of 0.78 for sur-
vival and 0.73 for PFS, or a 22% relative decrease in the risk of death and a 27% relative decrease in the risk of recurrence. After re-
currence, reoperation was performed in one-fifth of cohort I and in one-third of cohort II but was not effective (HR, 1.05 in cohort I and
1.02 in cohort II). Second-line chemotherapy, mainly consisting of nitrosourea-based chemotherapy, temozolomide, mitoxantrone,
fotemustine, and bevacizumab, improved survival in both cohorts (HR, 0.57 in cohort I and 0.74 in cohort II). Radiosurgery was also
effective (HR, 0.52 in cohort II).
Conclusions. We found a significant increase in overall survival, PFS, and survival after recurrence after 2004, likely due to improve-
ments in surgical techniques, introduction of the Stupp protocol as a first-line treatment, and new standard protocols for second-line
chemotherapy and radiosurgery after tumor recurrence. In both cohorts, reoperation after tumor recurrence did not improve survival.
Keywords: glioblastoma, surgery, survival analysis, treatments, treatment effectiveness.
Glioblastoma multiforme (GBM) (World Health Organization
grade IV astrocytoma)1 is the most common primary malignant
brain tumor in adults, accounting for 50%–60% of all incident
cases of gliomas and having the worst prognosis of all gliomas.
In Europe and North America, the incidence of GBM is 2–3 new
cases per 100 000 people per year.2 GBM incidence peaks be-
tween ages 45 and 70 years, and the disease occurs more
often in males.3,4 Well-established prognostic and predictive fac-
tors for survival are age, functional status on hospital admission
as measured by the Karnofsky Performance Scale (KPS), tumor
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extent, and surgical resection of the tumor.3,5,6 The Stupp proto-
col was approved by regulatory agencies as first-line treatment
for GBM after a clinical trial established that temozolomide, con-
comitant with radiotherapy and then as maintenance treatment,
improved survival and progression-free survival (PFS).7 The Stupp
protocol is now the standard treatment for patients with GBM,
and several studies have confirmed the beneficial effects of this
first-line regimen.6,8,9
Median survival for GBM patients after recurrence is 6
months.10 Bevacizumab alone or in combination with chemo-
therapy had been shown to be effective against recurrent
GBM,11,12 which led to its accelerated approval in May 2009 for
recurring patients.13 Increased survival after recurrence has also
been reported for patients given salvage radiosurgery.14,15
Conversely, the benefit of reoperation is still under discussion
and remains controversial. While some retrospective studies did
not report an increase in survival of patients with recurrent GBM
following second surgery,8,16,17 other studies have reported a sur-
vival benefit after reoperation, although this was mainly limited
to young patients with high KPS scores.5,18–21
In newly diagnosed GBM, methylation of the O6-methylguanine-
DNA methyltransferase (MGMT) promoter has been shown to
predict response to alkylating agents such as temozolomide.22
A recent meta-analysis also suggested that MGMT silencing is a
predictive marker that benefits patients who receive chemother-
apy as a component of adjuvant treatment.23
Here, we report the results of a comparison of survival and PFS
between 2 cohorts of patients with primary newly diagnosed GBM
treated at the Fondazione Istituto Neurologico Carlo Besta (INCB),
a tertiary-care institution in Milan, Italy.
Materials and Methods
Patients
The INCB Cancer Registry was used to prospectively enroll all consecutive
patients aged 16 years and older with a new diagnosis of histologically
confirmed primary GBM. Patients in cohort I17 (January 1997–December
2003) were followed up to April 2005, and those in cohort II (January
2004–December 2010) were followed up to April 2012. Secondary GBM
patients with previous histological or radiological diagnoses of low-grade
or anaplastic astrocytoma (WHO grade II or III astrocytoma) were
excluded. Pathological diagnosis was performed by 2 neuropathologists
at INCB in accordance with WHO guidelines.1 All patients provided written
informed consent to undergo surgery and chemoradiotherapy. Each was
Table 1. Characteristics of patients at baseline by cohort
Factor Cohort I (n¼ 490)a Cohort II (n¼ 764)b P value
No. of Patients (%) No. of Patients (%)
Sex
Male 295 (60.2%) 512 (67.0%) .01c
Female 195 (39.8%) 252 (33.0%)
Age (years)
≤50 127 (25.9%) 162 (21.2%) .07c
51–65 234 (47.8%) 364 (47.6%)
.65 129 (26.3%) 238 (31.2%)
KPSd
≤70 182 (37.9%) 157 (20.7%) ,.01c
.70 298 (62.1%) 603 (79.3%)
Tumor extent
Multiple lobes 226 (46.1%) 343 (45.1%) .73c
Single lobe 264 (53.9%) 417 (54.9%)
Surgery
Biopsy only 70 (14.3%) 45 (5.9%) ,.01c
Surgical resection 420 (85.7%) 719 (94.1%)
Treatment scheduled
Radiotherapy+ chemotherapye 304 (67.1%) 229 (31.3%) ,.01c
Stupp protocol 0 336 (45.9%)
Other protocolf 149 (32.9%) 167 (22.8%)
Median (95% CI) Median (95% CI)
Follow-up (months) 59.0 (95% CI, 38.7–73.5) 46.2 (95% CI, 35.3–54.6) .07g
aHistologically confirmed primary glioblastoma newly diagnosed between 1997 and 2003 and followed to April 2005.
bHistologically confirmed primary glioblastoma newly diagnosed between 2004 and 2010 and followed to April 2012.
cChi-square test.
dSum does not equal total because some values are missing.
eOther than Stupp protocol.
fCould be radiotherapy only, chemotherapy only, or no treatment.
gLog-rank test.
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also asked to give written consent for personal data to be used anonym-
ously for research purposes. The study was approved by the review board
of INCB.
Outcomes
Death certificates were collected from municipal offices yearly. Survival
was defined as time from the first surgery to death or the end of follow-up
(April 30, 2005, for cohort I or April 30, 2012, for cohort II). PFS was
defined as time from first surgery to first evidence of recurrence or
death, or the end of follow-up. Tumor recurrence was defined as the ap-
pearance of new lesions, a 25% increase in tumor extent on CT or MRI,
worsening of clinical/neurological condition, or increased need for corti-
costeroids as defined by the Macdonald criteria.24 The updated response
criteria published in April 2010 (RANO criteria)25 were not applicable to our
study. Survival after tumor recurrence was defined as time from tumor
recurrence to death or end of follow-up.
Predictors of Survival
Sex, age, preoperative KPS score (assessed on the day before surgery),
tumor extent (single lobe vs multiple lobes), surgery (resection vs biopsy),
and treatment schedule (Stupp protocol, radiotherapy plus chemotherapy
schedules differing from Stupp protocol, radiotherapy only, chemotherapy
only, or no treatment) were included in the survival model as predictors.
First-line chemotherapy was defined as any chemotherapy agent used
consecutively for at least 1 month.
Sex, age, time to recurrence (≥9 vs,9 months after the first surgery),
second-line chemotherapy (yes vs no), second-line radiotherapy (yes vs
no), and second surgery (yes vs no) were included in the analysis of sur-
vival after tumor recurrence.
MGMT status (methylated vs unmethylated) was tested as a predictor
of survival together with sex, age, KPS, tumor extent, and surgery. The
methylation status of the MGMT promoter was assessed using
methylation-specific PCR.26
Data
Data from both cohorts were compared to assess the predictive effect of
first-line treatments on overall survival (OS) and PFS and the effects of reo-
peration and second-line treatments on survival after recurrence. Ana-
lyses on PFS and survival after tumor recurrence were performed only
on patients actively followed-up at INCB. Survival by MGMT status was
analyzed on a subset of cohort II patients for whom test results were
available.
Statistical Analysis
A description of baseline patient characteristics was provided in terms of
percentages, and differences between the cohorts were evaluated using
the chi-square test for frequency and the log-rank test for median com-
parisons. OS and PFS were estimated using the Kaplan-Meier method and
Cox proportional hazards model.27 The Kaplan-Meier method was used to
obtain survival curves, survival medians, and probabilities at different time
points (1, 2, and 3 years for OS and 6, 12, and 18 months for PFS). The Cox
proportional hazards models provided hazard ratios (HRs) as relative risk
estimates of survival for given combinations of prognostic and predictive
factors(ie., sex, age, KPS, tumor extent, surgery, and treatment schedule).
Survival after recurrence was estimated using the Kaplan-Meier method
and a time-dependent Cox model that included sex, age, time to recur-
rence (cut-off¼ 9 months), reoperation, second-line chemotherapy, and
second-line radiotherapy.
Fig. 1. Kaplan-Meier curves of (A) overall survival, (B) progression-free
survival, and (C) survival after tumor recurrence by cohort: histologically
confirmed primary glioblastoma newly diagnosed between 2004 and
2010 and followed up to April 2012 (cohort II) vs confirmed primary
glioblastoma newly diagnosed between 1997 and 2003 and followed
up to April 2005 (cohort I). Analyses on progression-free survival and
survival after tumor recurrence were performed only on patients
actively followed at Fondazione Istituto Neurologico Carlo Besta.
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Results
Patients
The number of patients with GBM admitted to INCB increased by
56%, from 490 between 1997 and 2003 to 764 between 2004
and 2010. Survival status was verified for all patients, and the
completeness index of follow-up was 100%.28 Patient charac-
teristics are summarized in Table 1. In cohorts I and II, the
ratio of males to female was 1:0.7 and 1:0.5 (P¼ .01), respect-
ively, with 26.3% and 31.2% of patients over 65 years of age
(P¼ .07), KPS score .70 in 60% and 80% (P, .01), and
tumor confined to single lobe in more than 50% of the patients
in both cohorts (P¼ .73). Most patients (85.7% in cohort I and
94.1% in cohort II; P, .01) underwent surgical resection; the
remaining patients received biopsy only. Patients who received
a combination of radiotherapy and chemotherapy (different
from the Stupp protocol) were 67.1% in cohort I and 31.3% in
cohort II; none in cohort I and 45.9% in cohort II received the
Stupp protocol; 32.9% in cohort I and 22.8% in cohort II received
radiotherapy only, chemotherapy only, or no treatment (P, .01
for treatment schedule comparison between the 2 cohorts). The
most widely used first-line chemotherapies were nitrosourea-
based chemotherapy (74%) in cohort I, and temozolomide
(almost 90%) in cohort II. The postoperative radiotherapy
schedule was the same in both cohorts: external beam radiation
therapy of 60 Gy (fractionated into 1.8–2 Gy daily fractions)
targeting the enhancing portion of the tumor and a 2–3 cm
margin.
Follow-up ranged from 16.4 to 91.2 months in cohort I and
from 15.9 to 77.6 months in cohort II. Median follow-up was
59.0 months in cohort I and 46.2 months in cohort II (P¼ .07).
Comparison of Survival for Patients in Cohorts I and II
Fig. 1 shows Kaplan-Meier curves for OS (A), PFS (B), and survival
after tumor recurrence (C) for both cohorts. There was a statistic-
ally significant difference (log-rank tests, P, .01) between the 2
cohorts in the 3 survival curves.
At the end of follow-up, 24 (4.9%) cohort I and 91 (11.9%)
cohort II patients were still alive. In cohort I, the median OS
was 11.7 months (95% CI, 10.8–12.5 months), and survival prob-
abilities were 47% (95% CI, 43%–52%) at 1 year, 11% (95% CI,
8%–14%) at 2 years, and 5% (95% CI, 3%–7%) at 3 years. The
corresponding estimates for cohort II were median OS of 12.9
months (95% CI, 12.2–13.7 months), and survival probabilities
of 54% (95% CI, 52%–56%) at 1 year, 21% (95% CI, 20%–
22%) at 2 years, and 11% (95% CI, 10%–13%) at 3 years.
Table 2 shows the prognostic and predictive factors included in
the OS analysis with corresponding HRs for death, estimated
using a multivariable Cox proportional hazards model. Age, KPS,
tumor extent, surgery, and treatment schedule were prognostic
or predictive factors of OS in both cohorts. In cohort II, a
Table 2. Multivariable Cox proportional hazards modeling of overall survival by cohort
Factor Cohort I (n¼ 445)a Cohort II (n¼ 725)b
No. of Events/
No. of Patients




Male 259/274 1 435/486 1
Female 162/171 0.85 (0.69–1.05) 200/239 0.81 (0.68–0.96)
Age (years)c – 1.02 (1.01–1.03) – 1.02 (1.01–1.03)
KPS
≤70 158/162 1 142/148 1
.70 263/283 0.76 (0.62–0.94) 493/577 0.58 (0.48–0.70)
Tumor extent
Multiple lobes 192/205 1 305/329 1
Single lobe 229/240 0.82 (0.67–1.02) 330/396 0.79 (0.67–0.92)
Surgery
Biopsy only 59/60 1 42/42 1
Surgical resection 362/385 0.55 (0.40–0.74) 593/683 0.62 (0.44–0.85)
Treatment schedule
Radiotherapy+ chemotherapyd 276/298 1 211/228 1
Stupp protocol – – 263/333 0.78 (0.65–0.94)
Other protocole 145/147 2.75 (2.18–3.47) 161/164 2.66 (2.12–3.34)
aHistologically confirmed primary glioblastoma newly diagnosed between 1997 and 2003 and followed to April 2005. Forty-five cases withmissing data
for one or more covariates were excluded from the analysis.
bHistologically confirmed primary glioblastoma newly diagnosed between 2004 and 2010 and followed to April 2012. Thirty-nine cases with missing
data for one or more covariates were excluded from the analysis.
cContinuous variable.
dOther than Stupp protocol.
eCould be radiotherapy only, chemotherapy only, and no treatment.
Nava et al.: First- and second-line treatments in GBM survival
722
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/16/5/719/1196705
by Istituto Neurologico Carlo Besta user
on 23 August 2018
significant relative reduction of more than 20% (HR¼ 0.78; 95%
CI, 0.65–0.94) in the risk of death was observed for patients who
received the Stupp protocol, compared with those who received
radiotherapy and chemotherapy schedules other than the
Stupp protocol.
Based on 219 and 361 patients actively followed at INCB in
cohorts I and II, respectively, 10 (4.6%) cohort I and 35 (9.7%)
cohort II patients were still free from recurrence at the end of
follow-up. Median PFS was 5.7 months (95% CI, 5.0–6.4 months),
and PFS probabilities were 48% (95% CI, 42%–55%) at 6 months,
12% (95% CI, 8%–16%) at 12months, and 6% (95% CI, 3%–9%)
at 18 months, in cohort I. The corresponding estimates in cohort
II were a median PFS of 7.2 months (95% CI, 6.4–8.2 months),
and survival probabilities of 57% (95% CI, 52%–62%) at 6
months, 22% (95% CI, 18%–26%) at 12 months, and 13%
(95% CI, 9%–17%) at 18 months. Table 3 shows the prognostic
and predictive factors included in the PFS analysis with corre-
sponding HRs for recurrence, estimated by multivariable Cox pro-
portional hazards model. A significant relative reduction of about
30% (HR¼ 0.73; 95% CI, 0.58–0.92) in the risk of recurrence was
found for patients who received the Stupp protocol, compared
with those who received radiotherapy and chemotherapy treat-
ment schedules different from the Stupp protocol.
Two-hundred nine and 326 patients had tumor recurrence in
cohorts I and II, respectively. Ten (4.8%) cohort I and 44 (13.5%)
cohort II patients were still alive at the end of follow-up. In cohort
I, median survival after recurrence was 6.2 months (95% CI, 5.5–
7.3 months), and survival probabilities were 52% (95% CI, 46%–
59%) at 6 months, 21% (95% CI, 15%–27%) at 12 months, and
10% (95% CI, 5%–14%) at 18 months. The corresponding esti-
mates in cohort II were median survival after tumor recurrence
of 8.9 months (95% CI, 8.0–9.8 months), and survival probabil-
ities of 69% (95% CI, 63%–74%) at 6 months, 34% (95% CI,
29%–39%) at 12 months, and 17% (95% CI, 12%–21%) at 18
months. Table 4 shows the prognostic and predictive factors
included in the survival after recurrence analysis, with the corre-
sponding HRs for death estimated using a multivariable time-
dependent Cox model. The analysis revealed a significant relative
reduction in risk of death after recurrence for patients receiving
second-line chemotherapy (HR¼ 0.57; 95% CI, 0.41–0.79 for co-
hort I and HR¼ 0.74; 95% CI, 0.56–0.97 for cohort II), compared
with patients who did not receive second-line chemotherapy.
Second-line chemotherapy mainly consisted of nitrosourea-
based chemotherapy (49% in cohort I and 33% in cohort II),
temozolomide (21% in cohort I and 26% in cohort II), mitoxan-
trone (19% in cohort I and 10% in cohort II), fotemustine (18% in
cohort II only), and bevacizumab (5% in cohort II, only). The risk
of death after recurrence associated with second-line radiother-
apy was lower for patients in cohort II (HR¼ 0.52; 95% CI, 0.37–
0.75) than those in cohort I (HR¼ 0.94; 95% CI, 0.65–1.37).
Table 3. Multivariable Cox proportional hazards model for progression-free survival by cohort
Factor Cohort I (n¼ 206)a Cohort II (n¼ 353)b
No. of Events/
No. of Patients




Male 118/123 1 218/238 1
Female 80/83 0.87 (0.65–1.17) 101/115 0.84 (0.66–1.07)
Age (years)c – 1.02 (1.01–1.03) – 1.00 (0.99–1.01)
KPS
≤70 66/67 1 39/40 1
.70 132/139 0.61 (0.45–0.83) 280/313 0.71 (0.51–1.00)
Tumor extent
Multiple lobes 92/94 1 124/134 1
Single lobe 106/112 0.75 (0.55–1.02) 195/219 0.83 (0.66–1.05)
Surgeryd
Biopsy only 21/22 1 – –
Surgical resection 177/184 0.65 (0.40–1.07) – –
Treatment schedule
Radiotherapy+ chemotherapye 163/166 1 152/155 1
Stupp protocol – – 151/181 0.73 (0.58–0.92)
Other protocolf 35/40 1.82 (1.23–2.70) 16/17 2.35 (1.40–3.97)
aHistologically confirmed primary glioblastoma newly diagnosed between 1997 and 2003 and actively followed to April 2005 at INCB. Thirteen cases
had missing data for one or more covariates and were excluded from the analysis.
bHistologically confirmed primary glioblastoma newly diagnosed between 2004 and 2010 and actively followed to April 2012 at INCB. Eight cases with
missing data for one or more covariates were excluded from the analysis.
cContinuous variable.
dHR for surgery in cohort II was not calculated because there were too few cases in the reference category (4 of 353 patients had biopsy only in cohort
II).
eOther than Stupp protocol.
fCould be radiotherapy only, chemotherapy only, and no treatment.
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Second-line radiotherapy consisted of radio-immune therapy in
cohort I and of radiosurgery in cohort II. Reoperation after recur-
rence was not associated with increased survival in either cohort
(HR¼ 1.05; 95% CI, 0.71–1.54 in cohort I and HR¼ 1.02; 95% CI,
0.77–1.34 in cohort II). Sensitivity analyses performed excluding
patients who died within a month of reoperation did not change
the results (HR¼ 0.97; 95% CI, 0.66–1.44; n¼ 201 in cohort I and
HR¼ 0.96; 95% CI, 0.73–1.28; n¼ 299 in cohort II).
MGMT Methylation Analysis
Data on MGMT methylation were available for 240 (41%) of co-
hort II patients who underwent chemotherapy: 75 (31%) were
methylated, and 165 (69%) were unmethylated. Fig. 2 shows
Kaplan-Meier curves of OS for methylated and unmethylated
patients. At the end of follow-up (median OS, 16.8 months),
21 of the 75 methylated (28%) and 14 of the 165 (8%)
unmethylated patients were still alive. Survival probabilities
were 81% (95% CI, 73%–90%) and 68% (95% CI, 61%–75%)
at 1 year, 56% (95% CI, 45%–68%), and 20% (95% CI, 14%–
26%) at 2 years, 37% (95% CI, 24%–48%) and 8% (95% CI,
4%–12%) at 3 years, for methylated and unmethylated
patients, respectively. Survival for methylated patients was sig-
nificantly longer than for unmethylated patients, both in terms
of median OS (26.7 months; 95% CI, 21.8–34.5 months for
methylated vs 15.7 months, 95% CI, 13.3–16.8 months
for unmethylated; log-rank test, P, .01), and in terms of
HR adjusted for sex, age, tumor extent, KPS, and surgery
(HR¼ 0.45; 95% CI, 0.33–0.63; n¼ 238).
Discussion
OS in the 2004–2010 cohort was significantly better than that in
the 1997–2003 cohort, suggesting a relationship to the improve-
ments in surgical techniques and new protocols for first-line
chemotherapy and second-line radiosurgery that had become
available for cohort II. The number of patients with GBM admitted
to INCB was also significantly higher in the later period. The num-
ber of operating rooms available for neurosurgery increased from
2 to 4 starting in 2005. Furthermore, the number of GBM patients
presenting at INCB for treatment has increased over the last 7–8
years, so that the Institute now treats more patients than any
other center in Italy. INCB has always been a reference center
for neurosurgery in Italy and is now one of the relatively few cen-
ters designated by the Italian Health Ministry for such treatment.
Finally, the shorter median length of stay of cohort II than cohort
I (7 vs 12 days) probably reflects increasing concern for costs but
Table 4. Multivariable time-dependent Cox model for survival after recurrence by cohort
Factor Cohort I (n¼ 203)a Cohort II (n¼ 303)b
No. of Events/
No. of Patients




Male 115/121 1 186/206 1
Female 78/82 0.74 (0.55–0.99) 80/97 0.75 (0.57–0.98)
Age (years)c – 1.01 (1.00–1.02) – 1.02 (1.01–1.04)
Time to recurrenced
,9 months 154/158 1 185/198 1
≥9 months 39/45 0.76 (0.53–1.09) 81/105 0.65 (0.49–0.87)
Second-line chemotherapye
No 113/118 1 107/117 1
Yes 80/85 0.57 (0.41–0.79) 159/186 0.74 (0.56–0.97)
Second-line radiotherapyf
No 156/164 1 230/255 1
Yes 37/39 0.94 (0.65–1.37) 36/48 0.52 (0.37–0.75)
Second surgeryg
No 155/163 1 182/205 1
Yes 38/40 1.05 (0.71–1.54) 84/98 1.02 (0.77–1.34)
aHistologically confirmed primary glioblastoma newly diagnosed between 1997 and 2003 and actively followed to April 2005 at INCB. Six cases with
missing values of one or more covariates were excluded from the analysis.
bHistologically confirmed primary glioblastoma newly diagnosed between 2004 and 2010 and actively followed to April 2012 at INCB. Twenty- three
cases with missing values in one or more covariates were excluded from the analysis.
cContinuous variable.
dDefined as time from first surgery to tumor recurrence. Included in model as potential confounder only.
eDefined as first chemotherapy regimen received after tumor recurrence; consisted of procarbazine, temozolomide, fotemustine, mitoxantrone, and
bevacizumab in both cohorts. Included in the model as time-dependent covariate.
fDefined as a radiotherapy received after tumor recurrence; consisted of radio-immune therapy in cohort I and radiosurgery in cohort II. Included in the
model as time-dependent covariate.
gDefined as the first surgery performed after tumor recurrence. Included in the model as time-dependent covariate.
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also improvement in patient care, which in turn made volume
growth possible.
The 2 cohorts did not differ significantly for 2 established sur-
vival predictors (age and tumor extent) but did differ for presur-
gery functional status, which was better in cohort II patients.
Cohort II patients did not undergo first surgery earlier than
those in cohort I, since median times from radiologic diagnosis
to surgery were indistinguishable (27 days for cohort I vs 26
days for cohort II); however, earlier diagnosis in cohort II is pos-
sible, though we have no data to support this. A possible reason
why a greater proportion of cohort II patients underwent surgical
resection is that surgical techniques had improved considerably
for this cohort following the introduction of neuronavigation
tools, including ultrasound for real-time intraoperative naviga-
tion. To avoid biases due to these between-cohort differences,
we analyzed the 2 cohorts separately using multivariate methods
to adjust for potential confounding.
We found consistent results in terms of prognostic and predict-
ive factors in the 2 cohorts that indicated a reduction of more
than 20% in the relative risk of death and tumor recurrence
after the introduction of the Stupp protocol as first-line treat-
ment. A similar positive effect of the Stupp protocol has been
reported by other studies.8,9 However, compared with the Stupp
trial,7 we had slightly worse survival (median OS of 13.1 months
in our patients recruited after 2005; 14.6 months in Stupp), prob-
ably because our study was conducted in clinical practice, where-
as patients included in clinical trials are selected, have greater
treatment compliance, and typically survive longer.29,30 Two ob-
servational studies conducted in Northern Europe31,32 and a US
study33 also had similar results to ours: all compared patients
in the pre- and post-temozolomide era and found a favorable ef-
fect of the Stupp protocol with median OS of 9.7 to 12.0 months.
In our study, second-line chemotherapy (mainly consisting of
nitrosourea-based chemotherapy, temozolomide, mitoxantrone,
fotemustine, and bevacizumab), and radiosurgery were asso-
ciated with lower relative risk of death after tumor recurrence.
These findings, together with those of previous studies,14,15,34–
37 suggest that second-line treatments can prolong the survival
of patients with recurrent GBM. By contrast, we found that reo-
peration after tumor recurrence did not prolong survival in either
cohort. Other studies have also found that survival after recur-
rence was not noticeably better in patients undergoing further
surgical resection.8,16,17,38,39 Other studies again have found
that second surgery after recurrence does improve survival.5,18–
21 However, these studies reported only univariate analyses, rais-
ing the suspicion that the survival advantage may have been
affected by confounders. Indications for treatment and treat-
ment administration are often not standardized in observational
studies, and confounding by indication can lead to bias.40 In fact,
it has been reported that patient selection for second surgery can
be influenced by favorable prognostic factors such as young age,
high preoperative KPS score (≥80), small tumor volume
(≤50 cm3), and latency between first surgery and tumor recur-
rence of ≥6 months.41–43 In order to reduce the influence of se-
lection bias, we analyzed data using a multivariable model that
adjusted for several potential confounding factors.
In line with the results of a recent meta-analysis,23 we found
that MGMTmethylation status was a statistically significant inde-
pendent predictor of OS in patients with primary GBM, with a
.50% lower relative risk of death for methylated patients, com-
pared with unmethylated patients. These findings therefore con-
stitute additional evidence that this marker is useful in clinical
decision-making and that it may reduce treatment costs and tox-
icity in specific patient subgroups by withholding ineffective
medication.44
Drawing conclusions on the predictive effect of treatments
from cohort studies is difficult because the effects of treatments
are often overestimated by indication, selection, performance,
Fig. 2. Kaplan-Meier curves of overall survival by MGMT (O6-methylguanine-DNA methyltransferase) methylation status. Two-hundred forty patients
with histologically confirmed primary glioblastoma newly diagnosed between 2004 and 2010 and followed up to April 2012 underwent chemotherapy
and provided information on MGMTmethylation status. Survival by MGMT status was analyzed on a subset of cohort II patients for whom MGMT status
results were available.
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and detection bias.45,46 However, applying a multivariable ap-
proach in design and analysis, as we did, to determine outcome
predictors boosts confidence in the reliability of the estimates
thus derived. Randomized trials overcome selection bias and
confounding but have limited generalizability because of strict eli-
gibility criteria, low recruitment levels, or high levels of non-
consent,46 leading to findings inconsistent with daily practice.47
Provided putative predictive factors are interpreted cautiously,
our findings provide useful support for decision-making in clinical
practice as well as indications for future research. Since clinical
trials to resolve remaining uncertainties about the utility of reo-
peration following tumor recurrence are difficult to conduct, this
important clinical question should be resolved by carrying out
large prospective well-conducted cohort studies.
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